Study of the Week: A New Treatment Option for Lupus?
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on
Generalized arterial calcification of infancy (GACI) and autosomal recessive hypophosphatemia rickets type 2 (ARHR2) Awareness Day is recognized each year on Feb 1. This is
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we
In a previous post, I shared what it took to heal my eosinophilic esophagitis. In this post, I share a few tasty and healthy foods,
Prematurity and formula-feeding heighten the risk of necrotizing enterocolitis (NEC), a serious gastrointestinal issue. However, NEC is still poorly understood; in many cases, the
Doddie Aid, which begins January 1st and continues for the following six weeks, aims to encourage people to get active while raising funds to support
Have you ever heard of a natural history study? In short, a natural history study studies people who have, or are at risk of
There is no cure for multiple sclerosis (MS). However, treatment advances have helped people to live longer, happier lives. Current therapeutic options include corticosteroids,
In 2020, the U.S. FDA granted Orphan Drug designation to KB407, an investigational gene therapy for patients with cystic fibrosis (CF). More recently, at
Seven years ago, David and Amber Negele married. The pair couldn’t wait to begin their blissful wedded life together. Just a few years after their
From November 10-14, 2022, various stakeholders within the rheumatology sphere connected at the American College of Rheumatology’s (ACR) Convergence 2022. During ACR Convergence, described as
A January 2023 news release from biopharmaceutical company Avidity Biosciences, Inc. (“Avidity”) shares that the company’s therapy, AOC 1020, earned Fast Track designation from the
Currently, the standards-of-care for lupus include anti-malarial drugs such as hydroxychloroquine, corticosteroids and immune-suppressive therapies, and biologics such as Benlysta. But new therapies are urgently
SIGN UP FOR OUR NEWSLETTER |
|
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
What best describes you when it comes to rare disease? (check all that apply)
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.